The Phase 3b study found higher rates of complete skin clearance and weight loss with the combination than with Taltz alone in adults with plaque psoriasis and obesity or overweight.
Incyte announced Phase 3 results showing its tafasitamab plus lenalidomide regimen significantly improved progression-free survival in high-risk lymphoma patients.
